Liping Liu, founder, CEO & CSO of HighTide Therapeutics invited to present at the HKEX Biotech Week 2019 conference, 28-30 May in Hong Kong. Dr. Liu presented HighTide Therapeutics in the “Deep Dive Workshop” on Day 3.

HighTide Therapeutics, today announced that it has been invited to deliver two presentation at Phar-East 2019, to be held March 18–20 in Singapore.

Jeffrey Dao, Operations & Business Development Officer to present HighTide’s HTD1801 for primary sclerosing cholangitis (PSC) at the World Orphan Drug Congress USA 2019 in Oxon Hill, MD...

[Rockville, Maryland, Dec. 11, 2018] — HighTide Therapeutics, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9.

[Rockville, Maryland, Nov. 27, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced that the U.S. FDA has granted Fast Track Designation to its investigational new drug, HTD1801...

[Rockville, Maryland, October 3, 2018] — HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company participated in the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and...